Likewise, the elevated levels of circ-MYLK found in RCC suggests circ-MYLK is an oncogenic circRNA, that could be used as a diagnostic and prognostic biomarker of RCC, as well as a therapeutic target in the treatment of kidney cancer, since the inhibition of circ-MYLK should increase the circulating levels of miR-513a-5p and therefore reduce the expression levels of VEGF-C, blocking cancer metastasis. Here, MYLK is linked to renal cell carcinoma.